Serina Therapeutics Inc Cash Flow-to-Debt Ratio
Serina Therapeutics Inc cash flow-to-debt ratio. Serina Therapeutics Inc (SER) has a Cash Flow-to-Debt Ratio of -0.36x as of September 2025, meaning its operating cash flow of $-3.85 Million could theoretically repay 0% of its total liabilities ($10.82 Million) in one year. Check how high is Serina Therapeutics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Serina Therapeutics Inc (2016–2024)
Cash flow-to-debt ratio of Serina Therapeutics Inc from 2016 to 2024. Historical debt coverage capacity for Serina Therapeutics Inc across 9 annual periods. Check SER cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Serina Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2016–2024)
Serina Therapeutics Inc cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for Serina Therapeutics Inc. For the full cash flow conversion analysis, see Serina Therapeutics Inc (SER) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.76x | $-17.14 Million | $6.22 Million | ▼ -4494.3% |
| 2023 | -0.06x | $-2.48 Million | $41.26 Million | ▲ +40.6% |
| 2022 | -0.10x | $-2.08 Million | $20.56 Million | ▲ +32.6% |
| 2021 | -0.15x | $-2.25 Million | $15.03 Million | ▲ +82.1% |
| 2020 | -0.84x | $-7.82 Million | $9.32 Million | ▲ +60.2% |
| 2019 | -2.11x | $-10.16 Million | $4.83 Million | ▲ +35.7% |
| 2018 | -3.28x | $-8.00 Million | $2.44 Million | ▲ +31.6% |
| 2017 | -4.79x | $-6.29 Million | $1.31 Million | ▼ -1355.1% |
| 2016 | -0.33x | $-8.43 Million | $25.60 Million | — |